Functioning neuroendocrine neoplasms: Symptomatic control with 177Lu-DOTATATE

#4162

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE is recommended in unresectable and metastatic gastroenteropancreatic neuroendocrine neoplasms (NENs), however, recommendations for functioning NENs (F-NENs) are not well established. Besides PRRT impact in OS and PFS, real-life benefit in clinical control is also a relevant outcome, especially in F-NENs.

Aim(s): To assess symptomatic response to PRRT in F-NENs.

Materials and methods: A retrospective longitudinal study was performed including F-NENs treated with PRRT at our centre (2011-2023). Demographics, clinicopathological data, treatment details, symptomatic evolution, and best response in the 3-6 months following last cycle, were analysed.

Conference:

Presenting Author: Santos A

Authors: Lopes-Pinto M, Silva D, Ribeiro S, Oliveira J, Ferreira G,

Keywords: neuroendocrine neoplasm, functioning neuroendocrine neoplasm, carcinoid syndrome, PRRT,